Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders
This study aimed to summarize evidence and provide consensus-based guidelines for management of transplantation in patients with telomere biology disorders (TBD). Specifically, this review focuses on clinical management of lung, liver, and bone marrow transplantation in TBD patients.Recent FindingsTBD patients have specific unique biological vulnerabilities such as T cell immunodeficiency, susceptibility to infections, hypersensitivity to chemotherapy and radiation, and cytopenias. Furthermore, multiple organ involvement at diagnosis makes clinical management especially challenging due to higher degree of organ damage, and...
Source: Current Hematologic Malignancy Reports - February 5, 2024 Category: Hematology Source Type: research
Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation
CONCLUSIONS: Our preliminary observations suggest that an early application of ruxolitinib can safely and effectively prevent the occurrence of GVHD after allo-HSCT for the high-risk ALL patients. However, ruxolitinib may have a limited effect on preventing the ALL recurrence of high-risk patients.PMID:38302005 | DOI:10.1016/j.trim.2023.101978 (Source: Transplant Immunology)
Source: Transplant Immunology - February 1, 2024 Category: Transplant Surgery Authors: Qian Cheng Yishu Tang Feiyang Liu Xin Li Dan Fang Source Type: research
The Arc of Connectedness
It is perhaps surprising to realize that autologous bone marrow transplant (ABMT) was essentially an experimental therapy when we started our program in 1986. Upon reflection, it was the intersection of a very small, remarkably dedicated healthcare team and a group of engaged and energized patients, transplant survivors and their families, who helped propel the program to become the largest of its kind in Canada. That intersection morphed into close interactions among clinicians, other healthcare workers and patients, and led to several initiatives, unusual, if not unique at the time, that benefited patients, their relativ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Armand Keating Tags: Reflections Source Type: research
Towards Early Detection of Post-Allogeneic Bone Marrow Transplant Bronchiolitis Obliterans Syndrome (BOS) – the Use of Portable Airway Oscillometry
Bronchiolitis obliterans syndrome (BOS) is a devastating complication of allogeneic bone marrow transplantation (BMT). Detecting early small airway disease to diagnose BOS when it may be reversible could improve long term outcomes. Spirometry can be technically difficult for young and/or ill children. Oscillometry is novel pulmonary function assessment technology which superimposes pressure waves on normal tidal breathing, and the alterations in flow and pressure caused by the external waves are measured. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Eleanor Cook, Richard Cooper, Dr. Jane Koo, Kasiani C Myers, Jessica Lawson, Laura L. Walkup, Samuel B. Goldfarb, Stella M. Davies, Christopher Towe Tags: 173 Source Type: research
A High Proportion of Abnormal Pulmonary Baseline Investigations in Pediatric BMT Patients: Prospective, Multi-Center Results from the Transpire Study.
Pulmonary complications after allogeneic bone marrow transplant (BMT) are significant sources of morbidity and mortality. Pre-BMT pulmonary status may be a predictor of patient outcome, and can be affected by underlying diagnosis, age and prior therapy received. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Eleanor Cook, Steven Rose, Samuel B. Goldfarb, Matthew F. Abts, Jason C. Woods, Dr. Jane Koo, Richard Cooper, Jessica Lawson, Stephen Gilene, Sheri Ballard, Margaret L. MacMillan, Scott Baker, Laura L. Walkup, Stephanie L. Edwards, Kasiani C Myers, Stella Tags: 170 Source Type: research
Regimen Adherence Insights after Allogeneic Hematopoietic Stem Cell Transplantation from a Central Specialty Pharmacy
Adherence to the complex medication regimen is critical to minimize risk of graft-versus host disease and infectious complications and maximize success after aHSCT. The Transplant Pharmacy by CareDx is a centralized national specialty pharmacy serving multiple solid organ and bone marrow transplant programs and patients. Percentage of days covered (PDC) is a validated metric of medication regimen adherence that is used by this pharmacy. We sought to use PDC to identify factors associated with increasing nonadherence to medication regimen components. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: R Ashley Peden, Kimberly Lewis, Kristen Posey, Stuart Federman, Linda M Laub, James Gulley, Christopher R Ensor Tags: 645 Source Type: research
Eltrombopag Improved Cytopenias Due to Posttransplant Poor Graft Function: Experience from a Comprehensive Bone Marrow Transplantation Program in Jordan
Poor graft function (PGF) is a serious complication of allogeneic stem cell transplantation (allo-SCT). Current therapies are only partially effective. There are eight reports of eltrombopag given to improve posttransplant graft function with encouraging results. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Khalid Halahleh, Mohamad Makoseh, Isra Muradi, Rula Najjar, Waleed Da'na, Husam Abu-Jazar, Rawad Rihani Tags: 643 Source Type: research
Data Managers at Hematopoietic Cell Transplant Centers in Brazil: Overall Picture
Since 2016, efforts have been made toward consolidating the Brazilian Hematopoietic Cell Transplant and Cellular Therapy Registry (HCT-CT/BR) for a greater awareness of the current nationwide transplant activity and its outcomes. In 2019, the HCT-CT/BR was established in collaboration with the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the CIBMTR. However, for the registry to be maintained, data managers (DM) have to be qualified, for which the transplant center (TC) nurse has a crucial role. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Adriana Mendes Cavilha, Ms. Heliz Regina A. Neves, Cinthya Corr êa Silva, Antonio Macedo, Anderson João Simione, Paula Moreira da Silva Sabaini, Leonardo Jun Otuyama, Bruna Letícia da Silva Santos Geraldo, Mary E.D. Flowers, Eliana C M Miranda, Afonso Tags: 630 Source Type: research
Enhancing the Adherence of Cellular Therapy Centers to Multicenter DATA Registries: Impact of National Strategies
Hematopoietic cell transplantation (HCT) activity reported to multicenter data registries is a crucial means for understanding outcomes and the quality of HCT services. The Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) together with its HCT Data Managers Working Group (GTGD) have developed strategies to encourage centers to register their HCT performance using such databases. Those strategies are detailed in Figure 1. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Cinthya Corr êa Silva, Anderson João Simione, Paula Moreira da Silva, Leonardo Jun Otuyama, Antonio Macedo, Bruna Letícia da Silva Santos Geraldo, Ms. Heliz Regina A. Neves, Adriana Mendes Cavilha, Mary E.D. Flowers, Eliana C M Miranda, Afonso C Vigori Tags: 624 Source Type: research
“Navigating Growth: Expanding a Bone Marrow Transplant Unit in Compliance with FACT Standards"
Over a span of thirty years, our adult inpatient BMT Unit has undergone significant growth. With the increasing number of hematology referrals and the introduction of new therapies, capacity needed to expand. In the winter of 2022, a decision was made to annex the adjacent unit, creating a twenty-nine bed Bone Marrow Transplant Unit. This expansion necessitated the development of a new staffing model and associated clinical training. Additionally, it was imperative that compliance with the Foundation for the Accreditation of Cellular Therapy (FACT) standards was maintained. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Kimberlee Hanna, John A Odom, Jamie Palomo, Carole Elledge Tags: 575 Source Type: research
Implementing a BMT Nurse Navigator and Ambulatory BMT Nurse Journal Club
Journal clubs are effective at teaching nurses evidence-based practice (EBP) and improving patient outcomes. Inpatient Bone Marrow Transplant (BMT) BMT nurses have a journal club for role-specific EBP, but ambulatory BMT nurses such as BMT Nurse Coordinators do not currently have a venue to discuss role-specific EBP and new knowledge. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrea Fadel, Mylove Mortel, Buerkley Opalecky Tags: 570 Source Type: research
Predictors of Outcomes in Older Patients with Myelofibrosis – a Subset Analysis of the CIBMTR Database
Myelofibrosis is a clonal myeloid neoplasm with extramedullary hematopoiesis, peripheral cytopenia, bone marrow fibrosis, and varied systemic symptoms, including fever, weight loss, night sweats, and manifestations of cytopenia. In the presence of a suitable donor, an allogeneic stem cell transplant (allo-HSCT) is recommended treatment for younger patients with intermediate to high-risk myelofibrosis. Older age ≥55 years is considered to be an adverse prognostic factor for allo-HSCT in the European Bone Marrow Transplant (EBMT) model, but the outcomes of these patients are not well defined, despite myelofibrosis being a ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Muhammad Yasir, Dr. Muhammad Salman Faisal, Jennifer Bryant, Matthew Gravina, Moazzam Shahzad, Gerhard C Hildebrandt Tags: 564 Source Type: research
Characteristics of Multiple Myeloma Patients on Dialysis Who Receive Autologous Stem Cell Transplant
Renal impairment is part of the natural progression of multiple myeloma (MM); as such up to 40% of MM patients present with some degree of renal disease at diagnosis. Within this cohort, severe chronic kidney disease (CKD) requiring hemodialysis (HD) is present in up to 10% of MM patients. HD dependence may prevent clinicians from pursuing bone marrow transplant (BMT) referral, the current standard-of-care for MM, in this higher risk population for fear of increased complications. Here we explore the co-morbidities of MM patients on HD who receive autologous bone marrow transplantation (ABMT), as well as length of stay (LO...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Isabela L Pavkov, Danielle Bradshaw, Mohammad AH Mian, Vamsi Kota Tags: 547 Source Type: research
Blood Product Support in Multiple Myeloma Patients Undergoing Autologous Bone Marrow Transplantation May Predict Improved Outcome.
In this study, we observed the post ABMT outcomes in relation to the number of pRBC and Plt transfusions during post-transplant hospital stay. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Isabela L Pavkov, Mahran Shoukier, Mohammad AH Mian, Michael Stokes, Yazmin Reategui, Priyanshu Nain, Danielle Bradshaw, Anand Jillella, Vamsi Kota Tags: 540 Source Type: research
Barriers to Establishing a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Program without a Pre-Established Bone Marrow Transplant Program
Traditionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy is given at institutions with established bone marrow transplant (BMT) programs due to similarities of treatment and regulations between the two therapies. This can lead to limited access to a critical therapy for patients due to their geographical proximity to these facilities or their ability to travel. To improve access, the administration of CAR-T therapy needs to go beyond institutions with established BMT programs. However, due to high regulations and requirements surrounding CAR-T therapy, establishing a stand-alone CAR-T program is difficult and limite...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mrs. Krystal Waldrup, Ishmael Jaiyesimi, Lauren Burgett, Melissa Pirkola, Mrs. Adelaide van Lier, Annemarie Scanio, Kasey Thayer, Katie Gaches Tags: 436 Source Type: research
